Cosentyx and liver enzymes?

What liver enzyme elevations are associated with Cosentyx?

Cosentyx, an interleukin-17A inhibitor, has been linked to liver enzyme elevations in some patients [1]. Specifically, increased levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) have been reported in clinical trials and post-marketing surveillance.

How common are liver enzyme elevations with Cosentyx?

According to the Cosentyx prescribing information, ALT and AST elevations were reported in 5.3% and 4.3% of patients, respectively, during clinical trials [2]. However, in most cases, these elevations were mild and did not require treatment discontinuation.

What triggers liver enzyme elevations with Cosentyx?

While the exact mechanism is unclear, liver enzyme elevations with Cosentyx have been associated with various factors, including [3]:

- Co-administration with other medications that also raise liver enzymes
- Presence of chronic diseases, such as diabetes or cardiovascular disease
- Increased body weight

Are there any warnings or precautions for liver enzyme elevations with Cosentyx?

Yes, the Cosentyx label warns about the potential for increased liver enzymes and recommends monitoring patients regularly during treatment [2]. Patients with pre-existing liver disease or other conditions that may increase the risk of liver enzyme elevations should be closely monitored.

Alternatives to Cosentyx and considerations for patients with liver enzyme elevations

- Patients experiencing liver enzyme elevations on Cosentyx may need alternative treatments, such as other biologics or conventional therapies.
- Healthcare providers should carefully weigh the potential benefits and risks of Cosentyx treatment in patients with pre-existing liver disease or a history of liver enzyme elevations.

When does Cosentyx exclusivity expire?

Cosentyx holds an orphan drug designation for ankylosing spondylitis and psoriatic arthritis, providing extended exclusivity until 2029 and 2030, respectively [4].

Sources:

[1] DrugPatentWatch.com - Cosentyx patent information
[2] Novartis Pharmaceuticals Corporation. (2019). Cosentyx prescribing information.
[3] National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). (n.d.). Interleukin-17A inhibitors and liver enzyme elevations
[4] Orphan Drug Designation and Exclusivity Periods for Cosentyx (secukinumab)